ALGEN.PA Genoway

Healthcare Biotechnology Euronext Paris
1.97 EUR
Close of Nov 6, 2026
1.91 2.88
Market cap
EUR 24.4M
P/E
-
P/B
1.10x
ROE
-52.4%
Dividend yield
-
Fundamental score
2.0/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALGEN.PA undervalued?

Graham number

The Graham number of Genoway cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genoway fundamental analysis

6 of 11 checks passed

ROE 1/2

The stock's ROE falls within an average range (5.04%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

ROA 1/2

The stock's ROA (2.84%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

PBV 2/2

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

DER 1/2

The stock has a reasonable amount of debt compared to its ownership (56%), suggesting a balanced financial position and a moderate level of risk.

Revenue Growth 1/2

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

Net Profit Growth 2/2

This company has consistently achieved strong net profit growth over the past five years, demonstrating a solid financial performance and making it an appealing investment option.

Assets Growth 0/2

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

Graham Number 0/1

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

Dividend Growth 0/2

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

Dividend 0/2

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

Buffet Intrinsic Value 0/1

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Genoway stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genoway

genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick K…

Full company profile